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Edited by Jesus AvilaAbstract Human brain cellular prion protein (PrPc) is cleaved
within its highly conserved domain at amino acid 110/111 ﬂ 112.
This cleavage generates a highly stable C-terminal fragment
(C1). We examined the relative abundance of holo- and
truncated PrPc in human cerebral cortex and we found important
inter-individual variations in the proportion of C1. Neither age
nor postmortem interval explain the large variability observed
in C1 amount. Interestingly, our results show that high levels
of C1 are associated with the presence of the active ADAM10
suggesting this zinc metalloprotease as a candidate for the cleav-
age of PrPc in the human brain.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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ADAM101. Introduction
Prion diseases are a group of devastating brain diseases, that
includes Creutzfeldt–Jakob disease (CJD) and Gerstmann–
Stra¨ussler–Scheinker syndrome in humans [1]. The human
prion diseases can be sporadic, inherited or transmissible in
origin, and sporadic CJD comprises a broad spectrum of clin-
icopathological variants [2].
According to the protein only hypothesis, the mechanism for
prion propagation is thought to involve conversion of host
encoded cellular prion protein (PrPc) into conformers that
are insoluble and resistant to proteinase K (PrPres) and that
accumulates in prion-targeted tissues. In humans, the primary
sequence of PrPc (through a methionine–valine polymorphism
at codon 129) modulates the susceptibility to sporadic [3] and
variant CJD [4], the incubation period in iatrogenic CJD [5],
and the phenotype of the disease in sporadic CJD [6] and in
some genetic forms of the disease [7]. Thus, a better character-Abbreviations: ADAM10, a disintegrin and metalloproteinase domain
10; C1, C-terminal fragment; CJD, Creutzfeldt–Jakob disease; DNP,
dinitrophenyl; PNGase F, peptide, N-glycosidase F; PrPc, cellular
prion protein; PrPres, protease resistant PrP; SDS–PAGE, sodium
dodecyl sulfate–polyacrylamide gel electrophoresis
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doi:10.1016/j.febslet.2005.10.013ization of the biology of the PrPc is essential for the elucidation
of prion propagation in humans.
PrPc is expressed in most tissues and in particular in the cen-
tral nervous system [8]. Mature human PrPc spans residues 23–
231. The protein has an amino-terminal domain with a set of
octarepeats, a central hydrophobic domain, and a carboxy-ter-
minal region containing two Asn-linked glycosylation sites.
PrPc can be cleaved to generate a C-terminal fragment (C1).
In the brain, the normal processing of PrPc includes proteolysis
at residues 110/111 ﬂ 112 and generates a membrane-associ-
ated fragment called C1 [9] that is highly stable and that accu-
mulates at the plasma membrane [10].
Several mechanisms for PrPc truncation have been investi-
gated in vitro or in cells in culture including oxidation
[11,12] and a role for metalloproteases [13,14]. However, the
in vivo processing cellular machinery remains to be clariﬁed.
Here, we examined PrPc truncation and putative mechanisms
of the C1 fragment formation in a large number of non-CJD
human cases.2. Materials and methods
2.1. Preparation of human brain homogenates
The postmortem parietal isocortex was obtained from individuals
unaﬀected by prion diseases. Patient families gave informed consent
for the autopsy and tissues were collected according to the protocol
of the Neuropathology Department of the Salpeˆtrie`re Hospital (Paris,
France). Brain tissues were obtained from patients with the following
neuropathology conﬁrmed diagnoses: senile dementia of the Alzheimer
type (n = 8), fronto-temporal dementia (n = 2), adenocarcinoma with
metastasis and carcinomatous meningitis (n = 1), carcinomatous men-
ingitis (n = 1), and amyotrophic lateral sclerosis (n = 11). After the
autopsy, tissues were stored at 80 C.
Brain tissues were homogenized (30 mg tissue/ml) in ice-cold 10 mM
Tris, pH 7.4 containing protease inhibitors (P8340, Sigma, Saint Louis,
MO). Protein concentration was measured by the method of Lowry
et al. [15]. The absence of spontaneous in vitro cleavage of PrPc was
controlled, in a preliminary experiment, with the incubation of 20 lg
of proteins at 20 C for 0–4 h.2.2. Protein deglycosylation
Twenty lg of proteins were denatured and incubated with 0.125 U
of peptide N-glycosidase F (PNGase F; P0704L, New England Bio-
labs, Beverly, MA), at 37 C, for 2 h, according to the manufac-
turers instructions. The reaction was stopped by adding an equal
volume of 2· denaturing buﬀer (0.125 M Tris, pH 6.8; 4% wt/vol so-
dium dodecyl sulfate, 10% vol/vol 2-mercaptoethanol, and 20% vol/
vol glycerol).blished by Elsevier B.V. All rights reserved.
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The protein free carbonyl content was measured by forming protein
hydrazone derivatives using 2,4 dinitrophenyl (DNP) hydrazine
(42210, Fluka, Buchs, Switzerland) as described by Jolivalt et al.
[16]. Proteins were derivatized with an equal sample volume of
0.5 mM of 2,4 DNP hydrazine (pH 6.3) for 1 h at room temperature.
The reaction was stopped by adding an equal volume of 2· denaturing
buﬀer.
2.4. Western blot immunoassay
Proteins were separated by 12%, or 5–15% linear gradient, sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and
then transferred onto a poly(vinylidene diﬂuoride) membrane (Milli-
pore, Billerica, MA). Western-blotting was performed using anti-PrP,
anti-ADAM10 or anti-DNP antibodies and chemiluminescence
(RPN-2209; Amersham Biosciences, Freiburg, Germany) for the detec-
tion of peroxidase activity. The well-characterized SAF60 antibody
recognizes an epitope at human PrP residues 157–161 (Pharmacology
and Immunology Department, CEA/Saclay, France). Rabbit poly-
clonal anti-ADAM10 was from Chemicon (AB19026, Temecula,
CA). Polyclonal anti-DNP antibodies used for detection of free car-
bonyl groups of proteins were from Molecular Probes (A-6430, Eu-
gene, OR). Secondary antibody anti-mouse-HRP used was from
Amersham Biosciences (NA931) and secondary antibody anti-rabbit-
HRP used was from Sigma (A0545).
2.5. Densitometry analysis
Western blot ﬁlms were scanned (600 dpi; ImageScanner, Amersham
Pharmacia Biotech.) and regions of interest corresponding to full-
length PrPc, truncated PrPc, mature disintegrin and metalloproteinase
ADAM10 and immature ADAM10 were manually delimited using
ImageMaster Labscan v 3.00 (Amersham Pharmacia Biotech.). The
total signal intensity in the region of interest was corrected for back-
ground density. Values for C1 PrPc were calculated as a percentage
of total (full-length plus C1) PrPc. Values for mature ADAM10 were
calculated as a percentage of total (mature plus immature) ADAM10.
For the DNP derivatized proteins, all bands corresponding to stained
proteins were quantiﬁed.
2.6. Statistical analysis
Linear regression and correlation between C1 as a percent of total
PrPc and postmortem delay or age were carried out using StatView v
4.0 (Abacus Concepts, Berkeley, CA). The correlation analysis of C1Fig. 1. C1 fragment in the human brain. Electrophoretic pattern of PrPc i
proteins pretreated or not with PNGase F were separated by SDS–PAGE
spontaneous in vitro lysis (B). Parietal isocortex homogenate was incubated
treated with PNGase F and separated by SDS–PAGE. PrPc was detected
diﬂuoride) ﬁlter is shown as a loading control.as a percentage of total PrPc with DNP derivatized protein, or mature
ADAM10 as a percentage of total ADAM10, was carried out simi-
larly. A P value of less than 0.05 was considered to be statistically
signiﬁcant.3. Results
3.1. C1 fragment formation does not occur in vitro
SAF60 detected several bands representing heterogeneous
glycosylation of PrPc (27–34 kDa; Fig. 1A). After PNGase F
treatment, SAF60 recognized a band at 27 kDa (full-length
form of PrPc) and another band at 18 kDa (C1 fragment
described earlier by Chen et al. [9], corresponding to N-termi-
nally truncated form of PrPc). Since PNGase F treatment
allowed a clear separation of full-length and truncated forms
of PrPc, all subsequent analyses were carried out after enzy-
matic treatment.
To investigate whether the C1 fragment of PrPc was the
result of an in vitro lysis, we incubated a human isocortex
homogenate at 20 C. Fig. 1B shows that there was no varia-
tion in C1 amount even after 4 h incubation. This result clearly
indicates that there was no detectable in vitro formation of C1
fragment of PrPc in our experimental conditions.
3.2. Correlation between detection of C1 fragment and age,
postmortem delay and oxidation state of proteins
To study further the mechanism possibly involved in PrPc
cleavage in human brain, we examined a large series of cases
(n = 21) that varied in terms of age and postmortem interval.
To investigate the correlation between the relative amount of
C1 and age or postmortem interval, densitometric data from
Western blotting experiments were analyzed using simple lin-
ear regression (Fig. 2A and B). There was no signiﬁcant corre-
lation between the presence of C1 fragment and age
(R2 = 0.028; Fig. 2A). Similarly, when the relative abundance
of C1 was analyzed with respect to postmortem intervaln the human brain (A). Twenty lg of parietal isocortex homogenate
. PrPc was detected using SAF60 antibody. PrPc C1 and absence of
for 0–4 h at 20 C. Twenty lg of isocortex homogenate protein was
using SAF60 antibody. Coomassie staining of the poly(vinylidene
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Fig. 2. Level of PrPc C1 fragment and age, postmortem delay or brain
isocortex protein carbonyl content of the cases (A–C). Full-length and
truncated PrPc were vizualized by Western blotting of cerebral
isocortex from 21 cases. PrPc signal was quantiﬁed by densitometry.
The relative signal of C1 fragment is expressed as a percentage of total
PrPc (sum of full-length PrPc and C1 fragment) versus age (A),
postmortem delay (B) or brain isocortex protein carbonyl content (C).
Regression lines are shown.
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when the results were analyzed with respect to pathologies no
signiﬁcant diﬀerences were found (P > 0.10; Kruskal–Wallis
test). The value of P was superior to 0.35 when comparing
senile dementia of the Alzheimer type group to other diseases
group, and superior to 0.70 when comparing amyotrophic
lateral sclerosis group to other diseases group (Mann–Whitney
test).Since McMahon et al. [11] have reported the cleavage of
PrPc in cells in culture on exposure to reactive oxygen species,
we used a DNP hydrazone detection assay as a measure of oxi-
dative modiﬁcations in proteins. Regression analysis of the to-
tal dinitrophenylated protein signal with C1 in the 21 human
samples showed no correlation between oxidation state of pro-
teins and amount of PrPc fragment (R2 = 0.039; Fig. 2C).
3.3. Expression of the metalloprotease ADAM10 and PrPc
cleavage
The relative abundance of C-terminal PrPc fragment versus
total PrPc varied considerably between subjects as illustrated
in Fig. 3A for two representative cases. Because the metallo-
protease ADAM10 has been reported to cleave PrPc in vitro
[14], we examined the presence of the enzyme in brain homog-
enates. In samples treated with PNGase F (Fig. 3B), the anti-
ADAM10 antibody detected a prominent form of about
80 kDa representing the deglycosylated immature precursor
and a shorter and less abundant form of 55 kDa corresponding
to the active enzyme processed by furin [17]. The presence of
the detectable active form varied between cases but was not re-
lated to the intensity of the latent form. Interestingly, active
ADAM10 was readily detected in the sample that contained
the highest level of C1 fragment (case 2; Fig. 3A and B). Wes-
tern blot analyses for active ADAM10 were therefore carried
out in brain homogenates and combined with the analyses of
the relative abundance of C1. The mean of C1 fragment as a
percentage of total PrPc among individuals with detectable ma-
ture ADAM10 (n = 4) was 42% whereas this average was only
17% among those without detectable ADAM10 (n = 17;
p < 0.01, Mann–Whitney test; Fig. 3C). The amount of C1
fragment was signiﬁcantly correlated with mature ADAM10
measured in the 21 human samples (Spearman rank- order cor-
relation coeﬃcient: rs = 0.63, P < 0.005; Fig. 3D).4. Discussion
In the present study, we demonstrated that in the human
brain: (i) the proportion of the C-terminal C1 fragment of PrPc
was highly variable between individuals; (ii) high amount of
cleaved PrPc was associated with the presence of detectable ac-
tive zinc metalloprotease ADAM10.
The N-terminal region of PrPc is involved in the pathogenic
conversion of the molecule: (i) in vitro, PrPres formation is sig-
niﬁcantly reduced by deletion of residues 34–113 [18]; (ii) dom-
inant negative experiments showed that N-terminal
truncations of PrPc are less eﬀective inhibitors of PrPres forma-
tion than full-length PrPc [19]; (iii) work from Flechsig et al.
[20] suggests that a PrPc C-terminal fragment is eﬀective in
reversing the resistance of PrPc null mice to prion diseases,
but, incubation times are longer and PrPres is about 30-fold
lower than in wild-type mice. It seems that even if the absence
of the N-terminal part of PrPc might not completely prevent
transmissible spongiform encephalopathy diseases, it may slow
down the infection and therefore, PrPc truncation could be
considered as protective against prion disease propagation.
We can speculate that interindividual variations of PrPc trun-
cation, like those we observed, contribute to interindividual
variations in the incubation period and the disease duration
within genotype subgroups of cases with sporadic CJD and
transmitted forms of the disease.
Fig. 3. Expression of the metalloprotease ADAM10 and PrPc cleavage. Electrophoretic pattern of PrPc (A) and ADAM10 (B) in human brain.
Forty-ﬁve lg of protein of human parietal isocortex homogenates from 2 cases were separated by SDS–PAGE. PrPc was detected using SAF60
antibody (A). ADAM10 was detected using rabbit polyclonal antibodies (B). Search for an association between C1 fragment level and active
ADAM10 detection (C,D): The relative signal of C1 fragment expressed as a percentage of total PrPc (sum of full-length PrPc and C1 fragment) in 21
cases was statistically diﬀerent (\\, P < 0.01) between cases in which active ADAM10 was detected (n = 4) and the others (n = 17; C). The relative
signal of C1 fragment in 21 cases correlated with the relative signal of mature ADAM10 expressed as a percentage of total ADAM10 (sum of mature
and immature forms of ADAM10; D).
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face proteins can be proteolytically processed by the action of
a group of zinc metalloproteases. A previous study has shown
that C1 formation in brain homogenates could be blocked with
inhibitors of metalloproteases [13]. Further supports for a
metalloprotease-mediated mechanism in C1 formation have
come from studies of human embryonic kidney 293 transfected
cells in which the formation of C1 fragment was induced by
stably overexpressing human ADAM10 [14]. ADAM10, a
mammalian disintegrin metalloprotease, processes many mole-
cules such as ephrin-A2, a protein with a glycosylphosphat-
idylinositol anchor. We tested the hypothesis that ADAM10
may participate in C1 formation in vivo. When we used the
presence or absence of the active form of ADAM10 as a crite-
rion for separating the patients into two groups, we found that
the groups diﬀered signiﬁcantly in the levels of C1. Namely, in
brain homogenates from individuals in which mature
ADAM10 was detected, level of PrPc C1 was more than twice
as abundant as compared to individuals in which we did not
detect ADAM10. Taken together, our results are consistent
with a role for ADAM10 in PrPc cleavage in the human brain.
In summary, our results demonstrate an important interindi-
vidual variability in the abundance of truncated PrPc in the hu-man brain. We did also observe that the mature form of
ADAM10 was detected in individuals with higher levels of
the PrPc fragment supporting the notion that this metallopro-
tease contributes to PrPc cleavage. Finally, given that expres-
sion of truncated and full-length PrPc inﬂuences prion
propagation, this pathway may contribute to interindividual
variations in prion diseases progression.Acknowledgements: This work was supported in part by the GIS
‘‘Infections a` prions’’. B.A. Faucheux acknowledges funding from
the Assistance Publique-Hoˆpitaux de Paris (De´le´gation a` la Recherche
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